Madrigal changes the tune in Nash
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Akero’s imperfect Harmony
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
89bio’s home run fails to excite
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
Akero continues to pull ahead of Nash rivals
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
The crucial data readouts coming soon for small biotechs
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
